# Syncom Formulations India Ltd-$ (SYNCOMF)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹15.85
Day Change: +10.53%
52W High: ₹23.46
52W Low: ₹10.21
Market Cap: ₹1,283 Cr

## Valuation
P/E: 18.7
P/B: 3.33
EPS: ₹0.73
Book Value: ₹4.1
Dividend Yield: 0%

## Returns
1Y Return: -13.46%

## Profitability
ROE: 0%
ROCE: 21.49%
Debt/Equity: 0
Revenue Growth: -9.7%
Profit Growth: 64.3%
EBITDA Margin: 14.4%
Operating Margin: 17.24%

## About
Syncom Formulations India Ltd-$ is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Syncom Formulations India Ltd-$ makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Quarterly Report: Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations, 2015 Regarding Intimation Of Holding Board Meeting For Consideration And Approval Of The Standalone And Consolidated Audited Financial Results, As On 31St March, 2026
- Announcement: Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 Read With Master SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 Dated 30Th January, 2026.
- BSE Filing: Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 Read With Master SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 Dated 30Th January, 2026.

## Access
Current tier: anonymous
More history: Register free to see 6 more years.

## Data Freshness
Quote Updated: 2026-05-25T20:00:13.927Z
Price History Updated: 2026-05-25T05:33:13.128Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:33:13.128Z
Quant Updated: 2026-05-25T05:33:13.128Z
Sentiment Updated: 2026-05-25T05:33:13.128Z
Financials Status: current
Financials Updated: 2026-05-18T18:31:41.255Z
Financials Last Attempt: 2026-05-18T18:31:41.255Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2014)
Revenue: ₹115 Cr
Operating Profit: ₹11 Cr (OPM 9%)
Net Profit: ₹6 Cr
Tax: ₹8 Cr

## Annual P&L History
Mar 2014: Rev ₹115Cr | PAT ₹6Cr | OPM 9%
Mar 2015: Rev ₹151Cr | PAT ₹9Cr | OPM 11%
Mar 2016: Rev ₹173Cr | PAT ₹10Cr | OPM 11%

## Balance Sheet (Mar 2014)
Total Assets: ₹123 Cr
Total Liabilities: ₹123 Cr
Borrowings: ₹2 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Ankit Kedarmal Bankda, Executive Chairman
- Vijay Shankarlal Bankda B. Com LLB, MD and Executive & Non Independent Director
- Vaishali  Agrawal C.S., Company Secretary & Compliance Officer
- Rakesh Chandra Srivastava, Chief Marketing Officer
- Kedarmal Shankarlal Bankda M.Com, Whole-Time Director

---
Source: rupiya.io/stocks/syncomf
Disclaimer: For research and education only. Not investment advice.